These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26960749)

  • 1. Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1/STAT3 Signaling.
    Huang CY; Tai WT; Wu SY; Shih CT; Chen MH; Tsai MH; Kuo CW; Shiau CW; Hung MH; Chen KF
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):761-71. PubMed ID: 26960749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
    Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
    Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
    Tai WT; Shiau CW; Li YS; Chang CW; Huang JW; Hsueh TT; Yu HC; Chen KF
    J Hepatol; 2014 Jul; 61(1):89-97. PubMed ID: 24657398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
    Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
    Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.
    Chen KF; Su JC; Liu CY; Huang JW; Chen KC; Chen WL; Tai WT; Shiau CW
    Cancer Lett; 2012 Aug; 321(1):27-35. PubMed ID: 22465052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
    Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
    J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
    Tai WT; Shiau CW; Chen PJ; Chu PY; Huang HP; Liu CY; Huang JW; Chen KF
    Hepatology; 2014 Jan; 59(1):190-201. PubMed ID: 23908138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma.
    Fan LC; Shiau CW; Tai WT; Hung MH; Chu PY; Hsieh FS; Lin H; Yu HC; Chen KF
    Oncogene; 2015 Oct; 34(41):5252-63. PubMed ID: 25619838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
    Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
    J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZnAs@SiO
    Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
    Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
    [No Abstract]   [Full Text] [Related]  

  • 14. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.
    Huynh H; Chow PK; Tai WM; Choo SP; Chung AY; Ong HS; Soo KC; Ong R; Linnartz R; Shi MM
    J Hepatol; 2012 Mar; 56(3):595-601. PubMed ID: 22027573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
    Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
    Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.
    Huang CY; Lin CS; Tai WT; Hsieh CY; Shiau CW; Cheng AL; Chen KF
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):456-62. PubMed ID: 23474115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.
    Chen ZY; Shi M; Peng LX; Wei W; Li XJ; Guo ZX; Li SH; Zhong C; Qian CN; Guo RP
    J Transl Med; 2012 Dec; 10():245. PubMed ID: 23228017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sonic Hedgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma.
    Tsai CL; Hsu FM; Tzen KY; Liu WL; Cheng AL; Cheng JC
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1317-24. PubMed ID: 25682950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
    Tai WT; Shiau CW; Li YS; Chen YL; Chu PY; Huang JW; Hsu CY; Hsu YC; Chen PJ; Chen KF
    Mol Cancer Ther; 2014 Jan; 13(1):27-36. PubMed ID: 24275147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.